SCHEMBL6855227

SCHEMBL6855227

O=C1NN=C(c2nccs2)/C1=C/c1c(O)[nH]c2ccccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 6/20 0.56
PLK4 O00444 1/20 0.54
FLT3 P36888 1/20 0.54
MEN1 O00255 1/20 0.49
NPC1 O15118 1/20 0.49
TP53 P04637 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
GAA P10253 1/20 0.49
CYP2D6 P10635 1/20 0.49
MAPT P10636 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
RAB9A P51151 1/20 0.49
MAPK10 P53779 1/20 0.49
KMT2A Q03164 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
ALK Q9UM73 10/20 0.45
INSR P06213 4/20 0.45
FLT1 P17948 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6855231 1.00 KDR (0.56) KDRPLK4FLT3MEN1NPC1
SCHEMBL6859348 0.78 KDR (0.63) KDRFLT3MAPTALKINSR
SCHEMBL6859343 0.78 KDR (0.63) KDRFLT3MAPTALKINSR
SCHEMBL6855224 0.68 KDR (1.00) KDRPLK4FLT3MEN1NPC1
SCHEMBL6858182 0.67 KDR (0.57) KDRSMN1; SMN2ALKINSR
SCHEMBL6858185 0.67 KDR (0.57) KDRSMN1; SMN2ALKINSR
SCHEMBL7489879 0.65 GAA (0.39) KDRMEN1NPC1CYP1A2GAA
SCHEMBL7490457 0.65 CYP11B1 (0.46) KDRPLK4FLT3MEN1NPC1
SCHEMBL7490777 0.63 KDM4E (0.39) KDRPLK4FLT3MEN1MAPT
SCHEMBL7489423 0.61 GAA (0.45) MEN1NPC1CYP1A2GAACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831075-B2 Administering to a host for inhibiting kinase activity a 5-heterocylcic subustituted pyrazolone derivative CEPHALON, INC. 2004-12-14 US disclosed
US-20030162775-A1 Heterocyclic substituted pyrazolones CEPHALON, INC. 2003-08-28 US disclosed
US-6455525-B1 Heterocyclic substituted pyrazolones CEPHALON, INC. 2002-09-24 US disclosed
EP-1226141-A1 HETEROCYCLIC SUBSTITUTED PYRAZOLONES CEPHALON, INC. (US) 2002-07-31 EP disclosed
WO-2001032653-A1 HETEROCYCLIC SUBSTITUTED PYRAZOLONES CEPHALON, INC. (US) 2001-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162775-A1 Heterocyclic substituted pyrazolones CYP3A4, CYP3A5, PDXK KDR 3412/4885PLK4 1042/4885FLT3 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.